{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T10:57:15Z","timestamp":1704884235521},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T00:00:00Z","timestamp":1302048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s12325-011-0013-5","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T03:50:34Z","timestamp":1302580234000},"page":"367-388","source":"Crossref","is-referenced-by-count":11,"title":["Review of proton pump inhibitors for the initial treatment of heartburn: Is there a dose ceiling effect?"],"prefix":"10.1007","volume":"28","author":[{"given":"Pamela R.","family":"Kushner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Peura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,6]]},"reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.2004.051821","volume":"54","author":"J. Dent","year":"2005","unstructured":"Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710\u2013717.","journal-title":"Gut"},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N. Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u20131920.","journal-title":"Am J Gastroenterol"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2008.08.045","volume":"135","author":"P.J. Kahrilas","year":"2008","unstructured":"Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383\u20131391.e5.","journal-title":"Gastroenterology"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004836-200307000-00007","volume":"37","author":"C.G. Streets","year":"2003","unstructured":"Streets CG, DeMeester TR. Ambulatory 24-hour esophageal pH monitoring: why, when, and what to do. J Clin Gastroenterol. 2003;37:14\u201322.","journal-title":"J Clin Gastroenterol"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1365-2036.2009.04013.x","volume":"29","author":"R. Fass","year":"2009","unstructured":"Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with nonerosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261\u20131272.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2008.08.044","volume":"135","author":"P.J. Kahrilas","year":"2008","unstructured":"Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392\u20131413.","journal-title":"Gastroenterology"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3810\/pgm.2009.07.2019","volume":"121","author":"P.R. Kushner","year":"2009","unstructured":"Kushner PR, Snoddy AM, Gilderman L, Peura DA. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. Postgrad Med. 2009;121:67\u201375.","journal-title":"Postgrad Med"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2710.2004.00620.x","volume":"30","author":"L.D. Allgood","year":"2005","unstructured":"Allgood LD, Grender JM, Shaw MJ, Peura DA. Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn. J Clin Pharm Ther. 2005;30:105\u2013112.","journal-title":"J Clin Pharm Ther"},{"key":"13_CR9","first-page":"237","volume-title":"Handbook of Nonprescription Drugs: An interactive Approach to Self-Care","author":"A. Zweber","year":"2009","unstructured":"Zweber A, Berardi RR. Heartburn and dyspepsia. In: Berardi RR, ed. Handbook of Nonprescription Drugs: An interactive Approach to Self-Care. 16th edn. Washington, DC: American Pharmacists Association; 2009:237.","edition":"16th edn."},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00535-008-2214-5","volume":"43","author":"N. Uemura","year":"2008","unstructured":"Uemura N, Inokuchi H, Serizawa H, et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol. 2008;43:670\u2013678.","journal-title":"J Gastroenterol"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1365-2036.2003.01770.x","volume":"18","author":"M. Kulig","year":"2003","unstructured":"Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastrooesophageal reflux disease \u2014 an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767\u2013776.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00535-006-1804-3","volume":"41","author":"Y. Kinoshita","year":"2006","unstructured":"Kinoshita Y, Kobayashi T, Kato M, et al. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol. 2006;41:554\u2013561.","journal-title":"J Gastroenterol"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3109\/00365529709011212","volume":"32","author":"T. Lind","year":"1997","unstructured":"Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974\u2013979.","journal-title":"Scand J Gastroenterol"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2036.2003.01771.x","volume":"18","author":"P.O. Katz","year":"2003","unstructured":"Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003;18:875\u2013882.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1001\/archinte.160.12.1803","volume":"160","author":"J.E. Richter","year":"2000","unstructured":"Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000;160:1803\u20131809.","journal-title":"Arch Intern Med"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1046\/j.1365-2036.1999.00558.x","volume":"13","author":"J.E. Richter","year":"1999","unstructured":"Richter JE, Kovacs TO, Greski-Rose PA, Huang B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 1999;13:795\u2013804.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","volume":"100","author":"K.R. Devault","year":"2005","unstructured":"Devault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190\u2013200.","journal-title":"Am J Gastroenterol"},{"key":"13_CR18","volume-title":"pantoprazole sodium","author":"PROTONIX","year":"2010","unstructured":"PROTONIX (pantoprazole sodium) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc. 2010."},{"key":"13_CR19","volume-title":"prescribing information","author":"ZEGERID","year":"2010","unstructured":"ZEGERID [prescribing information]. San Diego, CA: Norwich Pharmaceuticals, Inc. 2010."},{"key":"13_CR20","volume-title":"prescribing information","author":"Dexilant","year":"2010","unstructured":"Dexilant [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc. 2010."},{"key":"13_CR21","volume-title":"prescribing information","author":"Nexium","year":"2008","unstructured":"Nexium [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2008."},{"key":"13_CR22","volume-title":"prescribing information","author":"Prevacid","year":"2009","unstructured":"Prevacid [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc. 2009."},{"key":"13_CR23","volume-title":"prescribing information","author":"Prilosec","year":"2008","unstructured":"Prilosec [prescribing information]. Wilmington, DE: AstraZeneca. 2008."},{"key":"13_CR24","volume-title":"prescribing information","author":"Aciphex","year":"2008","unstructured":"Aciphex [prescribing information]. Woodcliff Lake, NJ: Eisai Co., Ltd. 2008."},{"key":"13_CR25","first-page":"52","volume":"34","author":"W.S. Pray","year":"2009","unstructured":"Pray WS. Updates in nonprescription therapy for heartburn and GERD. US Pharm. 2009;34:52\u201355.","journal-title":"US Pharm"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2036.2009.04064.x","volume":"30","author":"D.A. Peura","year":"2009","unstructured":"Peura DA, Riff D, Snoddy AM, Fennerty MB. Clinical trial: lansoprazole 15 or 30 mg once daily vs placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol Ther. 2009;30:459\u2013468.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","volume":"179","author":"L.E. Targownik","year":"2008","unstructured":"Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319\u2013326.","journal-title":"CMAJ"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1503\/cmaj.080873","volume":"179","author":"J.B. Richards","year":"2008","unstructured":"Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008;179:306\u2013307.","journal-title":"CMAJ"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11894-008-0045-4","volume":"10","author":"G.A. Cote","year":"2008","unstructured":"Cote GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:208\u2013214.","journal-title":"Curr Gastroenterol Rep"},{"key":"13_CR30","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"Y.X. Yang","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947\u20132953.","journal-title":"JAMA"},{"key":"13_CR31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2036.2007.03381.x","volume":"26","author":"F. Pace","year":"2007","unstructured":"Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken \u2018on-demand\u2019. Aliment Pharmacol Ther. 2007;26:195\u2013204.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2036.2004.02085.x","volume":"20","author":"D. Armstrong","year":"2004","unstructured":"Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopynegative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20:413\u2013421.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR33","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1001\/archinte.160.12.1810","volume":"160","author":"J.E. Richter","year":"2000","unstructured":"Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000;160:1810\u20131816.","journal-title":"Arch Intern Med"},{"key":"13_CR34","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","volume":"97","author":"P. Miner Jr","year":"2002","unstructured":"Miner P, Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332\u20131339.","journal-title":"Am J Gastroenterol"},{"key":"13_CR35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/CEG.S12333","volume":"3","author":"R.C. Orlando","year":"2010","unstructured":"Orlando RC, Liu S, Illueca M. Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease. Clin Exp Gastroenterol. 2010;3:117\u2013125.","journal-title":"Clin Exp Gastroenterol"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000235953","volume":"80","author":"S. Haag","year":"2009","unstructured":"Haag S, Andrews JM, Katelaris PH, et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80:226\u2013234.","journal-title":"Digestion"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00228-009-0628-5","volume":"65","author":"T. Furuta","year":"2009","unstructured":"Furuta T, Sugimoto M, Kodaira C, et al. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol. 2009;65:693\u2013698.","journal-title":"Eur J Clin Pharmacol"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2036.2003.01539.x","volume":"17","author":"M. Kawamura","year":"2003","unstructured":"Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther. 2003;17:965\u2013973.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl5","key":"13_CR39","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.3949\/ccjm.70.Suppl_5.S4","volume":"70","author":"P.J. Kahrilas","year":"2003","unstructured":"Kahrilas PJ. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med. 2003;70(Suppl 5):S4\u2013S19.","journal-title":"Cleve Clin J Med"},{"issue":"Suppl5","key":"13_CR40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2004.02140.x","volume":"20","author":"D. Armstrong","year":"2004","unstructured":"Armstrong D. Review article: gastric pH \u2014 the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther. 2004;20(Suppl 5):19\u201326.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR41","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/bjs.4614","volume":"91","author":"A.D. Jenkinson","year":"2004","unstructured":"Jenkinson AD, Kadirkamanathan SS, Scott SM, Yazaki E, Evans DF. Relationship between symptom response and oesophageal acid exposure after medical and surgical treatment for gastrooesophageal reflux disease. Br J Surg. 2004;91:1460\u20131465.","journal-title":"Br J Surg"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MEG.0b013e3282f340b2","volume":"20","author":"G. Sarnelli","year":"2008","unstructured":"Sarnelli G, De GF, Efficie E, et al. Correlation between oesophageal acid exposure and dyspeptic symptoms in patients with nonerosive reflux disease. Eur J Gastroenterol Hepatol. 2008;20:264\u2013268.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"13_CR43","first-page":"1827","volume":"92","author":"D.J. Ott","year":"1997","unstructured":"Ott DJ, McManus CM, Ledbetter MS, Chen MY, Gelfand DW. Heartburn correlated to 24-hour pH monitoring and radiographic examination of the esophagus. Am J Gastroenterol. 1997;92:1827\u20131830.","journal-title":"Am J Gastroenterol"},{"key":"13_CR44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2006.03235.x","volume":"25","author":"P.O. Katz","year":"2007","unstructured":"Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2007;25:617\u2013628.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01713.x","volume":"18","author":"C. Calabrese","year":"2003","unstructured":"Calabrese C, Fabbri A, Bortolotti M, et al. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther. 2003;18:525\u2013532.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1572-0241.2005.40476.x","volume":"100","author":"C. Calabrese","year":"2005","unstructured":"Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol. 2005;100:537\u2013542.","journal-title":"Am J Gastroenterol"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.gtc.2010.08.009","volume":"39","author":"N. Parikh","year":"2010","unstructured":"Parikh N, Howden CW. The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am. 2010;39:529\u2013542.","journal-title":"Gastroenterol Clin North Am"},{"key":"13_CR48","first-page":"57","volume":"19","author":"T. Lobera","year":"2009","unstructured":"Lobera T, Navarro B, Del P, et al. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors. J Investig Allergol Clin Immunol. 2009;19:57\u201360.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"13_CR49","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1053\/j.gastro.2010.08.023","volume":"139","author":"Y.X. Yang","year":"2010","unstructured":"Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115\u20131127.","journal-title":"Gastroenterology"},{"key":"13_CR50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","volume":"149","author":"M. Sarkar","year":"2008","unstructured":"Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391\u2013398.","journal-title":"Ann Intern Med"},{"key":"13_CR51","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.2009.722","volume":"301","author":"S.J. Herzig","year":"2009","unstructured":"Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120\u20132128.","journal-title":"JAMA"},{"key":"13_CR52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1503\/cmaj.092129","volume":"183","author":"C.S. Eom","year":"2010","unstructured":"Eom CS, Jeon CY, Lim JW, et al. Use of acidsuppressive drugs and risk of pneumonia: systematic review and meta-analysis. CMAJ. 2010;183:310\u2013319.","journal-title":"CMAJ"},{"key":"13_CR53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","volume":"170","author":"M.D. Howell","year":"2010","unstructured":"Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784\u2013790.","journal-title":"Arch Intern Med"},{"key":"13_CR54","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinternmed.2010.73","volume":"170","author":"A. Linsky","year":"2010","unstructured":"Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772\u2013778.","journal-title":"Arch Intern Med"},{"key":"13_CR55","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","volume":"170","author":"S.L. Gray","year":"2010","unstructured":"Gray SL, Lacroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women\u2019s Health Initiative. Arch Intern Med. 2010;170:765\u2013771.","journal-title":"Arch Intern Med"},{"key":"13_CR56","unstructured":"FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm213206.htm#TableofEpidemiologicalstudiesevaluatingfractureriskwithprotonpumpinhibitors . Accessed March 11, 2011."},{"key":"13_CR57","volume-title":"product information","author":"Plavix","year":"2011","unstructured":"Plavix [product information]. Bridgewater, NJ: Bristol-Myers Squibb\/Sanofi Pharmaceuticals Partnership US; 2011. http:\/\/products.sanofiaventis.us\/PLAVIX\/PLAVIX.html . Accessed March 10, 2011."},{"key":"13_CR58","doi-asserted-by":"crossref","unstructured":"Kwok CS, Yeong JK, Loke YK. Meta-analysis: Risk of fractures with acid-suppressing medication. Bone. 2010; Dec 23. [Epub ahead of print].","DOI":"10.1016\/j.bone.2011.07.028"},{"key":"13_CR59","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1365-2036.2006.03127.x","volume":"24","author":"M. Jalving","year":"2006","unstructured":"Jalving M, Koornstra JJ, Wesseling J, Boezen HM, De JS, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341\u20131348.","journal-title":"Aliment Pharmacol Ther"},{"key":"13_CR60","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MCG.0b013e31817d3fa1","volume":"43","author":"G.M. Wilcox","year":"2009","unstructured":"Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. J Clin Gastroenterol. 2009;43:551\u2013553.","journal-title":"J Clin Gastroenterol"},{"key":"13_CR61","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2362.2010.02419.x","volume":"41","author":"D. Compare","year":"2010","unstructured":"Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2010;41:380\u2013386.","journal-title":"Eur J Clin Invest"},{"key":"13_CR62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12253-009-9192-7","volume":"16","author":"H. Wong","year":"2010","unstructured":"Wong H, Yau T, Chan P, et al. PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol Oncol Res. 2010;16:87\u201391.","journal-title":"Pathol Oncol Res"},{"key":"13_CR63","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.beem.2008.07.002","volume":"22","author":"S. Boonen","year":"2008","unstructured":"Boonen S, Dejaeger E, Vanderschueren D, et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab. 2008;22:765\u2013785.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"13_CR64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/cc6207","volume":"12","author":"C.V. Gould","year":"2008","unstructured":"Gould CV, McDonald LC. Bench-to-bedside review: Clostridium difficile colitis. Crit Care. 2008;12:203.","journal-title":"Crit Care"},{"issue":"Suppl1","key":"13_CR65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1523-5378.2009.00702.x","volume":"14","author":"A.C. Costa","year":"2009","unstructured":"Costa AC, Figueiredo C, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2009;14(Suppl 1):15\u201320.","journal-title":"Helicobacter"},{"key":"13_CR66","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1572-0241.2005.00285.x","volume":"100","author":"D.A. Johnson","year":"2005","unstructured":"Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100:1914\u20131922.","journal-title":"Am J Gastroenterol"},{"key":"13_CR67","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/pds.769","volume":"11","author":"A.A. Claessens","year":"2002","unstructured":"Claessens AA, Heerdink ER, van Eijk JT, Lamers CB, Leufkens HG. Characteristics of diarrhea in 10,008 users of lansoprazole in daily practice: which cofactors contribute? Pharmacoepidemiol Drug Saf. 2002;11:703\u2013708.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"13_CR68","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1542-3565(05)00023-6","volume":"3","author":"K.R. McQuaid","year":"2005","unstructured":"McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol. 2005;3:553\u2013563.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"13_CR69","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1572-0241.2005.41465.x","volume":"100","author":"C. Hawkey","year":"2005","unstructured":"Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol. 2005;100:1028\u20131036.","journal-title":"Am J Gastroenterol"},{"key":"13_CR70","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","volume":"2","author":"B.B. Dean","year":"2004","unstructured":"Dean BB, Gano AD, Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656\u2013664.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-011-0013-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0013-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T23:13:44Z","timestamp":1560122024000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-011-0013-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,6]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s12325-011-0013-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,6]]}}}